William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.
The administration of corticosteroids has many positive and negative effects in the long-term for patients with prostate cancer. The use of these agents should be personalized based on individual factors, such as diabetes. This utilization could also be utilized to help determine appropriate sequences.
Several new agents have been recently approved, each with a very unique mechanism of action. At this point, there is not a clear strategy for sequencing these agent but opportunities exist for personalization, such as not using corticosteroids in diabetic patients.